Advancing a New Treatment for Rheumatoid Arthritis
BEYOND is a Horizon Europe-funded project dedicated to advancing the clinical development of SOL-116, Lipum’s first-in-class antibody for rheumatoid arthritis. Led by Lipum and carried out in collaboration with Age Labs, CHDR and MERAccess, the project brings together expertise in clinical development and biomarker research to support a Phase IIa proof-of-concept study and generate the evidence needed to advance SOL-116 towards the next stage of development.
Advancing a New Treatment for Rheumatoid Arthritis
BEYOND is a Horizon Europe-funded project dedicated to advancing the clinical development of SOL-116, Lipum’s first-in-class antibody for rheumatoid arthritis. Led by Lipum and carried out in collaboration with Age Labs, CHDR and MERAccess, the project brings together expertise in clinical development and biomarker research to support a Phase IIa proof-of-concept study and generate the evidence needed to advance SOL-116 towards the next stage of development.
About BEYOND
BEYOND is a Horizon Europe-funded collaboration bringing together Lipum, Age Labs, CHDR and MERAccess to advance the development of SOL-116 for rheumatoid arthritis. Through expertise in clinical development, biomarkers and health economics, the project aims to generate the evidence needed to support future regulatory approval, reimbursement and patient access.
Our journey with SOL-116
The partners in the project
Supported by Horizon Europe
BEYOND has received funding from the European Union’s Horizon Europe research and innovation programme. The project supports the advancement of SOL-116 into a Phase IIa proof-of-concept study in rheumatoid arthritis, helping accelerate the development of a potential new treatment for patients with chronic inflammatory diseases.
SOL-116
SOL-116 represents a new generation of biological therapies for rheumatoid arthritis. Developed by Lipum, the candidate is based on a novel mechanism of action targeting BSSL, with the ambition of improving treatment options for patients affected by chronic inflammatory disease. Supported by the BEYOND project, SOL-116 is progressing into the next stage of clinical development.
